x

Loading data...

x

Loading data...

AHMEDABAD: Ahmedabad-based drug maker Zydus Cadila has received the final approval from the USFDA to market anti-diabetic drug Pioglitazone HC1 tablets in the US markets.

According to the company's press statement, the estimated sales in 2012 as per IMS for Pioglitazone HCl tablets was $2 billion. The US drug authorities (USFDA) approved the tablets in different strengths of 15 mg, 30 mg and 45 mg.

The group now has 75 approvals and has so far filed 170 ANDAs since the commencement of filing process in FY 2003-04.